emc易倍官网入口Skip to main content
Ipsen Home Page
Press shift tab to select search category
Loading...
  • Newsroom arrow down
      < Back
    • Newsroom
    • Press Releases
    • emc易倍官网入口Media Updates
    • Media Resources
    • Media Contacts
    • emc易倍官网入口Subscribe
  • Investors arrow down
      < Back
    • Investors
    • emc易倍官网入口Investors
    • Financial Results
    • Annual Reports & Regulated Information
    • Investor Events & Financial Calendar
    • Shareholder Information
    • Subscribe
    • Ratings & Bonds
  • Careers arrow down
      < Back
    • Careers
    • Careers
    • Working at Ipsen
    • Culture
    • emc易倍官网入口Job Search
  • Contacts arrow down
      < Back
    • Contacts
    • emc易倍官网入口Contacts
    • Our Locations
    • Report Side Effects
    • Subscribe
  • Press shift tab to select search category
    Loading...
  • emc易倍官网入口         EN  arrow_down
    • English EN
    • Fran?ais FR
  •  Global
    <
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • Middle East & Africa
    • emc易倍官网入口 United States
    • Brazil
    • Canada
    • Mexico
    • Australia
    • China
    • emc易倍官网入口 Singapore
    • South Korea
    • Japan
    • Belgium
    • Ukraine
    • UK
    • emc易倍官网入口 Germany
    • France
    • Nordics
    • emc易倍官网入口 Greece
    • emc易倍官网入口 Italy
    • Netherlands
    • Spain
    • Poland
    • Russia
    • emc易倍官网入口 Czech Republic
    • Switzerland
    • emc易倍官网入口 Austria
    • UAE & Gulf
    • Saudi Arabia
  • Home
  • Company
      < Back
    • Company
    • Company
    • Leadership
    • History
    • Fondation Ipsen
  • Expertise
      < Back
    • Expertise
    • Oncology
    • Rare Disease
    • Neuroscience
    • Medicines
  • Science
      < Back
    • Science
    • Science
        < Back
      • Science
      • Oncology
      • Rare Disease
      • Neuroscience
    • Profiles
    • Partnering
        < Back
      • Partnering
      • Therapeutic focus
      • Meet the team
    • Clinical Trials
        < Back
      • Clinical Trials
      • Lay Summaries
      • emc易倍官网入口Find Clinical Trials
    • emc易倍官网入口Pipeline
  • Sustainability
      < Back
    • Sustainability
    • Sustainability
    • Environment
    • Patients
    • People
    • Governance
    • Our Standards
  • Patients
      < Back
    • Patients
    • Patients
    • emc易倍官网入口Together for Oncology
    • emc易倍官网入口Together for Rare Disease
    • Together for Neuroscience
    • emc易倍官网入口Collaborate with us
  • Stories
  1. Home
  2. Newsroom – Subscribe to Ipsen News

emc易倍官网入口

IPN price

€160.00

 €-0.60 (-0.37%)

  • Media Resources
  • Annual Report
  • Contacts
  • Our Locations
Ipsen logo
LinkedIn Instagram Facebook Youtube
  • Terms and Conditions
  • Cookie Policy
  • Global Privacy Policy

? Ipsen Pharma. All rights reserved - 2026

You are now leaving the Ipsen group global website. To continue, please click on Continue?

Continue
We value your feedback

How easy was it to navigate Ipsen website and locate the information you were seeking?






2026-05-22 23:18:34